TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.30
−1.66%Oct 23, 2026, 21:30 UTC
Traws Pharma, Inc. agreed to file an SEC registration statement to register the resale of shares issued under its common stock purchase agreement with Roth Principal Investments LLC.
Oct 23, 2026, 21:30 UTC
Traws Pharma, Inc. entered into a common stock purchase agreement giving it the right, but not the obligation, to sell up to $50 million of common stock to Roth Principal Investments LLC over 36 months at a 6% discount to VWAP.
Aug 14, 2026, 20:30 UTC
Traws Pharma reported its financial results for the quarter ended June 30, 2026, and provided business highlights including updates on its lead clinical programs and its April 2026 financing.
Source:Jul 9, 2026, 00:00 UTC
Traws Pharma, Inc. elected Iain Dukes, Werner Cautreels, Trafford Clarke, John Leaman, and Nikolay Savchuck as directors, effective July 8, 2026.
Jun 12, 2026, 21:30 UTC
Traws Pharma deferred its planned Phase 2a human influenza challenge study of tivoxavir marboxil after a negative review by the UK's Medicines and Healthcare Products Regulatory Agency.